Solid Biosciences Inc.

/Solid Biosciences Inc.

Their mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.


Final Price

Anticipated Shares

Effective Date
January 26, 2018


To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange